Cargando…
An update on long-acting therapies in chronic sight-threatening eye diseases of the posterior segment: AMD, DMO, RVO, uveitis and glaucoma
In the real-world setting, there is suboptimal compliance with treatments that require frequent administration and assessment visits. This undertreatment frequently has negative consequences in eye disease and carries a real risk to vision. For example, patients with glaucoma risk progression of vis...
Autores principales: | Ghanchi, Faruque, Bourne, Rupert, Downes, Susan M., Gale, Richard, Rennie, Christina, Tapply, Ian, Sivaprasad, Sobha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9151779/ https://www.ncbi.nlm.nih.gov/pubmed/34974541 http://dx.doi.org/10.1038/s41433-021-01766-w |
Ejemplares similares
-
Evaluation of real-world early response of DMO to aflibercept therapy to inform future clinical trial design of novel investigational agents
por: Halim, Sandra, et al.
Publicado: (2020) -
The impacts of COVID-19 on glaucoma patient outcomes as assessed by POEM
por: Pujari, Rathin, et al.
Publicado: (2021) -
Low-dose cyclosporine treatment for sight-threatening uveitis: Efficacy, toxicity, and tolerance
por: Mathews, D, et al.
Publicado: (2010) -
Five-year visual acuity outcomes and injection patterns in patients with pro-re-nata treatments for AMD, DME, RVO and myopic CNV
por: Wecker, Thomas, et al.
Publicado: (2017) -
C©đmo me qued©♭ calvo /
por: Grunberg, Arnon
Publicado: (2004)